IMR Press / FBL / Volume 16 / Issue 8 / DOI: 10.2741/3886

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
JAK-STAT signaling in hepatic fibrosis
Show Less
1 Ludwig Boltzmann Institute for Cancer Research, Waehringer Strasse 13a, A-1090 Vienna, Austria
2 Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Waehringer Strasse 13a, A-1090 Vienna, Austria
3 Institute for Cancer Research, Medical University of Vienna (MUV), Borschkegasse 8, A-1090 Vienna, Austria
Academic Editor:Serge Haan
Front. Biosci. (Landmark Ed) 2011, 16(8), 2794–2811;
Published: 1 June 2011
(This article belongs to the Special Issue Regulation of signalling in health and disease)

Chronic liver injury, liver fibrosis and formation of hepatocellular carcinoma are intimately linked and represent a major medical challenge since treatment options are limited. Therefore, it is important to identify cellular and molecular pathways that promote liver damage or provide hepatoprotection for development of therapeutic approaches. Recently, the transcription factors STAT3 and STAT5 have been implicated in liver fibrosis induced by cholestatic liver damage. In this review, we summarize our current knowledge about STAT proteins in liver fibrosis and focus on common activities that underlie the hepatoprotective mechanisms regulated by IL-6/gp130/STAT3 and GH/STAT5/IGF-1 signaling pathways.

Back to top